NHERF1 (Na+/H+ exchanger 3 regulating factor 1) is an integral membrane adaptor protein carrying two NH2-terminal PDZ (postsynaptic density 95/discs large/zona occludens 1) tandem domains.1 PDZ1 (11-97 amino acids) and PDZ2 (150-237 amino acids) show 74% identity to each other and bind to specific carboxyl-terminal motifs on target proteins, such as -catenin and PTEN, that may have a pivotal role in tumorigenesis. Oncogenic activity of NHERF1 is strictly dictated by changes on its subcellular localization.1,2 A pharmacophore model was used to filter out an in-house training set of about 6000 compounds, leading to identify a potent inhibitor of NHERF1.3 We herein reported the design and synthesis of new NHERF1 inhibitors (Figure 1).4 The new compounds were synthesized by treating the appropriate indole with thionyl chloride and the proper amino derivative in the presence of pyridine in dichloromethane at room temperature for 12 h; alternatively, the coupling reaction was carried out using (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate and triethylamine in N,N-dimethylformamide at room temperature for 12 h. Compounds 5, 9, 10 and 13 exhibited a remarkable cytotoxicity in Ls174TshBeta-Cat cells. The binding to NHERF1 PDZ was confirmed by means of a dansylated peptide corresponding to the C-terminal sequence of Beta2-AR. When used in combination with antagonists of Beta-catenin, the new derivatives increased the apoptotic death of colorectal cancer cells refractory to currently available Wnt/Beta-catenin-targeted agents. References 1. Vaquero, J.; Nguyen Ho-Bouldoires, T. H.; Clapéron, A.; Fouassier, L. Oncogene 2017, 36, 3067‒3079. 2. Georgescu, M. M.; Morales, F. C.; Molina, J. R.; Hayashi, Y. Curr. Mol. Med. 2008, 8, 459−468. 3. Saponaro, C.; Sergio, S.; Coluccia, A.; De Luca, M.; La Regina, G.; Mologni, L.; Famiglini, V.; Naccarato, V.; Bonetti, D.; Gautier, C.; Gianni, S.; Vergara, D.; Salzet, M.; Fournier, I.; Bucci, C.; Silvestri, R.; Gambacorti Passerini, C.; Maffia, M.; Coluccia, A. M. L. Oncogene 2018, 37, 3301‒3316. 4. Coluccia, A.; La Regina, G.; Naccarato, V.; Nalli, M.; Orlando, V.; Biagioni, S.; De Angelis, M. L.; Baiocchi, M.; Gautier, C.; Gianni, S.; Di Pastena, F.; Di Magno, L.; Canettieri, G.; Coluccia, A. M. L.; Silvestri, R. ACS Med. Chem. Lett. 2019, 10, 499‒503.
Small molecule inhibitors of kdm5 histone demethylases increase the radiosensitivity of breast cancer cells overexpressing JARID1B / La Regina, G.; Naccarato, V.; Masci, D.; Puxeddu, M.; Nalli, M.; Coluccia, A.; Negri, R.; Silvestri, R.. - (2019), pp. 177-177. (Intervento presentato al convegno XXVI National Meeting in Medicinal Chemistry - XII Young Medicinal Chemists’ Symposium tenutosi a Milano).
Small molecule inhibitors of kdm5 histone demethylases increase the radiosensitivity of breast cancer cells overexpressing JARID1B
La Regina, G.;Naccarato, V.;Masci, D.;Puxeddu, M.;Nalli, M.;Coluccia, A.;Negri, R.;Silvestri, R.
2019
Abstract
NHERF1 (Na+/H+ exchanger 3 regulating factor 1) is an integral membrane adaptor protein carrying two NH2-terminal PDZ (postsynaptic density 95/discs large/zona occludens 1) tandem domains.1 PDZ1 (11-97 amino acids) and PDZ2 (150-237 amino acids) show 74% identity to each other and bind to specific carboxyl-terminal motifs on target proteins, such as -catenin and PTEN, that may have a pivotal role in tumorigenesis. Oncogenic activity of NHERF1 is strictly dictated by changes on its subcellular localization.1,2 A pharmacophore model was used to filter out an in-house training set of about 6000 compounds, leading to identify a potent inhibitor of NHERF1.3 We herein reported the design and synthesis of new NHERF1 inhibitors (Figure 1).4 The new compounds were synthesized by treating the appropriate indole with thionyl chloride and the proper amino derivative in the presence of pyridine in dichloromethane at room temperature for 12 h; alternatively, the coupling reaction was carried out using (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate and triethylamine in N,N-dimethylformamide at room temperature for 12 h. Compounds 5, 9, 10 and 13 exhibited a remarkable cytotoxicity in Ls174TshBeta-Cat cells. The binding to NHERF1 PDZ was confirmed by means of a dansylated peptide corresponding to the C-terminal sequence of Beta2-AR. When used in combination with antagonists of Beta-catenin, the new derivatives increased the apoptotic death of colorectal cancer cells refractory to currently available Wnt/Beta-catenin-targeted agents. References 1. Vaquero, J.; Nguyen Ho-Bouldoires, T. H.; Clapéron, A.; Fouassier, L. Oncogene 2017, 36, 3067‒3079. 2. Georgescu, M. M.; Morales, F. C.; Molina, J. R.; Hayashi, Y. Curr. Mol. Med. 2008, 8, 459−468. 3. Saponaro, C.; Sergio, S.; Coluccia, A.; De Luca, M.; La Regina, G.; Mologni, L.; Famiglini, V.; Naccarato, V.; Bonetti, D.; Gautier, C.; Gianni, S.; Vergara, D.; Salzet, M.; Fournier, I.; Bucci, C.; Silvestri, R.; Gambacorti Passerini, C.; Maffia, M.; Coluccia, A. M. L. Oncogene 2018, 37, 3301‒3316. 4. Coluccia, A.; La Regina, G.; Naccarato, V.; Nalli, M.; Orlando, V.; Biagioni, S.; De Angelis, M. L.; Baiocchi, M.; Gautier, C.; Gianni, S.; Di Pastena, F.; Di Magno, L.; Canettieri, G.; Coluccia, A. M. L.; Silvestri, R. ACS Med. Chem. Lett. 2019, 10, 499‒503.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
